Britain’s medicines regulator said on Thursday it had approved AstraZeneca’s antibody-based treatment to prevent COVID-19 in people whose immune response is poor.
Britain’s medicines regulator said on Thursday it had approved AstraZeneca’s antibody-based treatment to prevent COVID-19 in people whose immune response is poor.